Naslov: | Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells |
---|
Avtorji: | ID Omerzel, Maša (Avtor) ID Jesenko, Tanja (Avtor) ID Markelc, Boštjan (Avtor) ID Cerovšek, Anja (Avtor) ID Serša, Gregor (Avtor) ID Čemažar, Maja (Avtor) |
Datoteke: | URL - Izvorni URL, za dostop obiščite https://sciendo.com/article/10.2478/raon-2022-0009
PDF - Predstavitvena datoteka, prenos (1,01 MB) MD5: 95B8226E6DBEADAF47600F94FC387EB9
|
---|
Jezik: | Angleški jezik |
---|
Tipologija: | 1.01 - Izvirni znanstveni članek |
---|
Organizacija: | OI - Onkološki inštitut Ljubljana
|
---|
Povzetek: | One of the new treatment options for unresectable locally advanced pancreatic cancer is electro-chemotherapy (ECT), a local ablative therapy that potentiates the entry of chemotherapeutic drugs into the cells, by the application of an electric field to the tumor. Its feasibility and safety were demonstrated in preclinical and clinical studies; however, there is a lack of preclinical studies assessing the actions of different drugs used in ECT, their mechanisms and interactions with other target drugs that are used in clinical practice. Materials and methods. The aim of the study was to determine the cytotoxicity of two chemotherapeutic drugs usually used in ECT (bleomycin and cisplatin) in the BxPC-3 human pancreatic carcinoma cell line and evaluate the interactions of ECT with the targeted drug sunitinib. First, the cytotoxicity of ECT using both chemotherapeutics was determined. In the next part, the interactions of ECT and sunitinib were evaluated through determination of combined cytotoxicity, sunitinib targets and kinetics of cell death.Results. The results demonstrate that ECT is effective in pancreatic cancer cell line, especially when bleomycin is used, with the onset of cell death in the first hours after the treatment, reaching a plateau at 20 hours after the treat-ment. Furthermore, we provide the rationale for combining ECT with bleomycin and the targeted drug sunitinib to potentiate cytotoxicity. The combined treatment of sunitinib and ECT was synergistic for bleomycin only at the high-est used concentration of bleomycin 0.14 μM, whereas with lower doses of bleomycin, this effect was not observed. The interaction of ECT and treatment with sunitinib was confirmed by course of the cell death, also indicating on synergism |
---|
Ključne besede: | electrochemotherapy, pancreas, sunitinib, pancreatic cancer |
---|
Status publikacije: | Objavljeno |
---|
Verzija publikacije: | Objavljena publikacija |
---|
Datum objave: | 01.06.2022 |
---|
Založnik: | Association of Radiology and Oncology |
---|
Leto izida: | 2022 |
---|
Št. strani: | str. 164-172 |
---|
Številčenje: | Vol. 56, no. 2 |
---|
Izvor: | Ljubljana |
---|
PID: | 20.500.12556/DiRROS-19761 |
---|
UDK: | 616-006-085 |
---|
ISSN pri članku: | 1318-2099 |
---|
DOI: | 10.2478/raon-2022-0009 |
---|
COBISS.SI-ID: | 105234179 |
---|
Avtorske pravice: | by Authors |
---|
Datum objave v DiRROS: | 24.07.2024 |
---|
Število ogledov: | 290 |
---|
Število prenosov: | 168 |
---|
Metapodatki: | |
---|
:
|
Kopiraj citat |
---|
| | | Objavi na: | |
---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |